Fraser Orthopaedic Institute, University of British Columbia, New Westminster, BC, Canada ; and.
Virginia Commonwealth University Medical Center, Richmond, VA .
J Orthop Trauma. 2024 Jun 1;38(6):333-337. doi: 10.1097/BOT.0000000000002804.
To determine the early implant failure rate of a novel retrograde intramedullary femoral nail.
Retrospective cohort study.
Academic level 1 trauma center.
Patients aged 18 years and older with an acute OTA/AO 32-A, 32-B, 32-C, and 33-A fractures or periprosthetic distal femur fracture from April 2018 to April 2022 were included in the study. The 2 interventions compared were the Synthes Expert retrograde/antegrade femoral nail (or control implant) versus the next-generation retrograde femoral nail (RFN)-advanced retrograde femoral nail (RFNA or experimental implant) (Synthes, West Chester, PA).
Early implant-related complications between the experimental and control implants were assessed including locking screw back out, screw breakage, intramedullary nail failure, need for secondary surgery, and loss of fracture reduction.
Three hundred fourteen patients were identified with a mean age of 31.0 years, and 62.4% of the patients being male. Open fractures occurred in 32.5% of patients with 3.8% of injuries being distal femur periprosthetic fractures. Fifty-six patients were in the experimental group and 258 patients in the control group. Mean follow-up was 46.8 weeks for the control cohort and 21.0 weeks for the experimental cohort. Distal interlocking screw back out occurred in 23.2% (13 of 56) of the experimental group patients and 1.9% (5 of 258) of the control group patients ( P < 0.0001). Initial diagnosis of interlocking screw back out occurred at an average of 3.2 weeks postoperatively (range, 2-12 weeks). Fifty-four percent of patients who sustained screw back out underwent a secondary operation to remove the symptomatic screws (12.5% of all patients treated with the experimental implant required an unplanned secondary operation due to screw back out). A logistic regression model was used to predict screw back out and found the experimental implant group was 4.3 times as likely to experience distal locking screw back out compared with the control group ( P = 0.01).
The retrograde femoral nail-advanced implant was associated with a significantly higher rate of screw back out with a substantial number of unplanned secondary surgeries compared with the previous generation of this implant.
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
确定新型逆行髓内钉的早期种植体失败率。
回顾性队列研究。
学术水平 1 级创伤中心。
2018 年 4 月至 2022 年 4 月期间,年龄在 18 岁及以上的急性 OTA/AO 32-A、32-B、32-C 和 33-A 骨折或股骨假体远端骨折的患者。比较的两种干预措施为 Synthes Expert 逆行/顺行股骨钉(或对照植入物)与新一代逆行股骨钉(RFN)-先进逆行股骨钉(RFNA 或实验植入物)(Synthes,West Chester,PA)。
确定了 314 名患者,平均年龄为 31.0 岁,其中 62.4%为男性。32.5%的患者发生开放性骨折,3.8%的患者为股骨假体远端骨折。实验组 56 例,对照组 258 例。对照组的平均随访时间为 46.8 周,实验组为 21.0 周。实验组患者中有 23.2%(13 例)出现远端交锁螺钉脱出,对照组患者中有 1.9%(5 例)(P<0.0001)。最初诊断为交锁螺钉脱出的时间平均为术后 3.2 周(范围,2-12 周)。54%发生螺钉脱出的患者因症状性螺钉而接受二次手术(由于螺钉脱出,接受实验性植入物治疗的所有患者中有 12.5%需要计划外的二次手术)。使用逻辑回归模型预测螺钉脱出,发现实验组发生远端锁定螺钉脱出的可能性是对照组的 4.3 倍(P=0.01)。
与前一代逆行股骨钉相比,新型逆行股骨钉-高级植入物的螺钉脱出率显著更高,且需要大量计划外的二次手术。
治疗性 III 级。有关证据水平的完整说明,请参阅作者说明。